Sign inJoin waitlistJoin the waitlist

Carla Casulo

Assistant Director of Cancer Research Training and Education · Wilmot Cancer Institute

Credentials: · · · · ·

History

Cancer Research Training and Education · Wilmot Cancer Institute
Present
Wilmot Cancer Institute
Present
University of Rochester School of Medicine and Dentistry
Present

Memorial Sloan-Kettering Cancer Center
2008–2011
Yale New Haven Hospital, York Street Campus
2005–2007
Yale New Haven Hospital, York Street Campus
2004–2005
SUNY Downstate Health Sciences University - College of Medicine
2004

Research

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the…
Journal of Clinical Oncology · 2015 · First of 12 authors · 720 citations
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
The Lancet Oncology · 2022 · 573 citations
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections
Clinical Lymphoma · 2013 · First of 3 authors · 255 citations

Jonathan Friedberg
43 papers
BK
Brad Kahl
28 papers
Christopher Flowers
25 papers
Paul Barr
18 papers
BL
Brian Link
17 papers
Thomas Habermann
17 papers
Jonathon Cohen
16 papers
Peter Martin
16 papers
Izidore Lossos
15 papers
Loretta Nastoupil
15 papers
Patrick Reagan
14 papers · 1 as a fellow
AZ
Andrew Zelenetz
12 papers

Clinical trials

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
Principal investigator · Recruiting · Phase 2
University of Rochester
2019–2027
A Phase II Study of Doxycycline in Relapsed NHL
Principal investigator · Terminated · Phase 2
University of Rochester
2014–2015
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2031